Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, Alsayed Y, Waheed S, Petty N, Epstein J, Shaughnessy JD Jr, Tricot G, Zangari M, Zeldis J, Barer S, Crowley J.
Barlogie B, et al. Among authors: epstein j.
Blood. 2008 Oct 15;112(8):3115-21. doi: 10.1182/blood-2008-03-145235. Epub 2008 May 20.
Blood. 2008.
PMID: 18492953
Free PMC article.
Clinical Trial.